Global Pharma Industry Regulators Seek Unified Approach To Remote Inspections
Executive Summary
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
You may also be interested in...
Preparing For The Return Of US FDA Inspections
Compared to FY2019, FDA data show agency inspections of OTC and Rx drug manufacturing facilities in FY2020 fell 60%. As pandemic continues in FY2021, inspection rate will remain depressed, and it remains unclear how the agency will reduce the backlog without resorting to remotely conducted inspections.
Pandemic Will Continue Limiting US FDA Inspections In Driving FY 2021 Drug GMP Warnings
FDA historically has based 100% of drug adulteration warning letters on inspections but COVID-19-related travel restrictions began changing that in FY 2020, when 2% of drug GMP warning letters were based on testing import samples. The change became even more pronounced in the first two months of FY 2021, with 59% of actions related to sample testing and 41% to inspections.